<DOC>
	<DOC>NCT02897219</DOC>
	<brief_summary>The objective of this study is to confirm efficacy of ASP1941 based on the changes in HbA1c and to assess its safety in subjects with type 1 diabetes mellitus receiving ASP1941 once daily in combination with insulin for 24 weeks. This study will also assess the safety/efficacy of long-term treatment (52 weeks).</brief_summary>
	<brief_title>A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>This study consists of two parts. In Part 1, ASP1941 or placebo will be administered orally in a blind manner. In Part 2, the long-term safety and efficacy of ASP1941 will be evaluated in patients who have participated in the study and completed the Part 1.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>The subject has been diagnosed with type 1 diabetes mellitus The subject has been receiving insulin therapy for the treatment of diabetes mellitus. The subject has not switched from an insulin product to another insulin product or switched between continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). The subject has an HbA1c value between 7.5% and 11.0% and the difference of HbA1c value is within ± 2.0%. The subject has a fasting blood Cpeptide level &lt; 0.6 ng/mL. The subject has a body mass index (BMI) between 20.0 kg/m2 and 35.0 kg/m2. The subject has type 2 diabetes mellitus. The subject has participated in a clinical study or post marketing study of another drug or medical equipment within 12 weeks (84 days) before providing written informed consent, or is currently participating in such a study. The subject has received treatment with ASP1941 (ipragliflozin) or participated in a clinical study of ASP1941 (excluding subjects who discontinued before the investigational period). The subject participated in this study previously. The subject has received a hypoglycemic agent other than insulin or an αglucosidase inhibitor. The subject has proliferative retinopathy (except for those who have undergone photocoagulation etc. and whose symptoms are stable). The subject has experienced severe hypoglycemia. The subject has experienced diabetic ketoacidosis. The subject has chronic disease that requires the continuous use of corticosteroids, immunosuppressants, etc. The subject has symptomatic urinary tract infection or symptomatic genital infection. The subject has a history of recurrent urinary tract infection or recurrent genital infection. The subject has a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, or another serious heart disease. The subject has a concomitant malignant tumor or a history of malignant tumor The subject has a history of an allergy to ASP1941 (ipragliflozin) and/or similar drugs (drugs possessing SGLT2 inhibitory action). The subject has psychiatric disorder that is inappropriate for participation in the study. The subject has drug addiction or alcohol abuse. The subject has severe infection or serious trauma, or is perioperative. The subject has a history of medically significant renal disease such as renovascular occlusive disease, nephrectomy and/or renal transplant. The subject has any symptoms of dysuria, anuria, oliguria, or urinary retention. The subject has severe renal impairment or endstage renal failure requiring dialysis. The subject has an Aspartate Aminotransferase and/or Alanine Aminotransferase value that exceeds 2 times, or a total bilirubin value that exceeds 1.5 times the upper limit of the reference range. The subject has uncontrolled severe hypertension. The subject has serious gastrointestinal disease or a history of operation for serious gastrointestinal disease.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SGLT2 inhibitor</keyword>
	<keyword>ASP1941</keyword>
	<keyword>type 1 diabetes mellitus</keyword>
</DOC>